{
    "clinical_study": {
        "@rank": "168265", 
        "arm_group": [
            {
                "arm_group_label": "High dose group", 
                "arm_group_type": "Experimental", 
                "description": "Fang yi qing feng shi granule, Oral,10g, 3 times a day, Oral,for 3 months Methotrexate,Oral,7.5-15mg per week Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
            }, 
            {
                "arm_group_label": "Low dose group", 
                "arm_group_type": "Experimental", 
                "description": "Fang yi qing feng shi granule,Oral,10g, 2 time a day, taking morning and evening,for 3 months.\nplacebo,Oral,10g, 1 time a day, taking noon ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
            }, 
            {
                "arm_group_label": "The placebo group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo,Oral,10g, 3 time a day ,for 3 months. Methotrexate,Oral,7.5-15mg per week. Acetaminophen tablets,Oral,0.5g, 1~2 times a day, when vas=10."
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to evaluate the efficacy and safety of Fang yi qing Feng shi\n      granules in subjects with Rheumatoid Arthritis."
        }, 
        "brief_title": "The Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Rheumatoid Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Rheumatoid"
            ]
        }, 
        "detailed_description": {
            "textblock": "Fang yi qing feng shi granules is the chinese patent medicine, which contains 8 kinds of\n      chinese medicine .\n\n      Fang yi qing feng shi granules was approved by China Food and Drug Administration (CFDA) in\n      2005, produced by means of modern technology by Maoxiang Group Jilin Pharmaceutical Co.,\n      Ltd.The study is a multi-center, double -blind, placebo -controlled, randomized in Chinese\n      subjects with Rheumatoid Arthritis to assess treatment effect and safety in the subjects\n      treated with Fang yi qing feng shi granules versus subjects treated with placebo."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects have the diagnosis of Rheumatoid Arthritis in active state.\n\n          2. Subjects have the Traditional Chinese Medicine (TCM) diagnosis ofArthralgic Syndrome\n             with the sign of dampness obstructing connecting vessel\u3002\n\n          3. Subjects must stop the medicine at least three month\uff0cwhich is Diseases modifying\n             anti-rheumatic drugs(including glucocorticoids).\n\n          4. Male or female subjects, between the ages of 18 and 65 years old.\n\n          5. Joint function grading and ray classification are both in \u2160\uff5e\u2162.\n\n          6. Subjects agree to participate in this study and sign the informed consent form.\n\n        Exclusion Criteria:\n\n          1. Subjects with systemic lupus erythematosus,sicca syndrome, or severe osteoarthropathy\n             will be excluded.\n\n          2. Subjects with severe rheumatic arthritis are loss of ability\n\n          3. Allergic to test drugs(basic treatment or drug combination),Allergic\n             constitution(Allergic to two or more drugs).\n\n          4. Female subject who was pregnant or breast-feeding or considering becoming pregnant.\n\n          5. Subjects with sever diseases in Cardiovascular, brain, lung, liver, kidney and\n             hematopoietic system.\n\n          6. The Liver function (ALT,AST) and kidney function\uff08BUN,Cr\uff09is higher than normal.\n\n          7. The Blood Routine (leukocyte count,platelet count)is lower than normal.\n\n          8. Subject considered by the investigator, for any reason, to be an unsuitable candidate\n             for the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029599", 
            "org_study_id": "China.JLMXFYQ2008-01"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "High dose group", 
                    "Low dose group"
                ], 
                "description": "10g, Oral,Three each time, 3 times a day,for 3 months;", 
                "intervention_name": "Fang yi qing feng shi granule", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Low dose group", 
                    "The placebo group"
                ], 
                "description": "10g, Oral,Three each time, 3 times a day,for 3 months", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "High dose group", 
                    "Low dose group", 
                    "The placebo group"
                ], 
                "description": "7.5-15mg per week\uff0cAll patients should be used", 
                "intervention_name": "Methotrexate", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "High dose group", 
                    "Low dose group", 
                    "The placebo group"
                ], 
                "description": "Oral,0.5g, 1~2 times a day, when vas=10", 
                "intervention_name": "Acetaminophen tablets", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Acetaminophen", 
                "Methotrexate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": [
            {
                "contact": {
                    "email": "songyjgm@126.com", 
                    "last_name": "Yuejin Song", 
                    "phone": "+86-13995674345"
                }, 
                "facility": {
                    "address": {
                        "city": "Wuhan", 
                        "country": "China", 
                        "state": "Hubei"
                    }, 
                    "name": "Hubei provincial hospital of tcm"
                }, 
                "investigator": {
                    "last_name": "Yuejin Song", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lnzyjd@sina.com", 
                    "last_name": "Mingli Gao", 
                    "phone": "+86-13704047929"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "Hospital of Liaoning University of Traditional Chinese Medicine"
                }, 
                "investigator": {
                    "last_name": "Mingli Gao", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "wangjuyong1@126.com", 
                    "last_name": "Li Su", 
                    "phone": "+86-021-64385700-1319"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "LONGHUA Hospital Shanghai University of TCM"
                }, 
                "investigator": {
                    "last_name": "Li Su", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "fengshiliuwei@163.com", 
                    "last_name": "Wei liu", 
                    "phone": "+86-13516161000"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin"
                    }, 
                    "name": "First Teaching hospital of Tianjin University of Traditional Chinese Medicine"
                }, 
                "investigator": {
                    "last_name": "wei liu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "tcmerc@126.com", 
                    "last_name": "Fushun Gu", 
                    "phone": "+86-13820683026"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin"
                    }, 
                    "name": "Second affiliated hospital of Tianjin university of tcm"
                }, 
                "investigator": {
                    "last_name": "Fushun Gu", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2 Randomised, Double-blind, Placebo-controlled Multiple Ascending Dose Study Evaluate the Efficacy and Safety of Fang yi Qing Feng Shi Granules in Subjects With Rheumatoid Arthritis", 
        "overall_official": {
            "affiliation": "First Teaching Hospital of Tianjin University of Traditional Chinese Medicine", 
            "last_name": "wei liu", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The percentage of  Therapeutic effect with American College of Rheumatology standards  (ACR)", 
            "safety_issue": "No", 
            "time_frame": "Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029599"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The symptoms and signs include \"Tender joint count,swollen joint count,time of morning stiffness,mean grip strength, VAS score,Jint function\"", 
                "measure": "The change  of Rheumatoid Arthritis (RA) associated symptoms and signs", 
                "safety_issue": "No", 
                "time_frame": "Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week"
            }, 
            {
                "measure": "Safety assessments will be based on adverse event reports and the results of vital sign measurements, electrocardiogram, physical examinations, and clinical laboratory tests", 
                "safety_issue": "Yes", 
                "time_frame": "Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week"
            }, 
            {
                "measure": "The subjects of their comprehensive evaluation of disease activity(AIMS),The observer to the comprehensive evaluation of disease activity in the study(AIMS),The subjects of physical function evaluation(HAQ).", 
                "safety_issue": "No", 
                "time_frame": "Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week"
            }, 
            {
                "measure": "The change of  laboratory test indexes (ESR\u3001RF\u3001CRP)", 
                "safety_issue": "No", 
                "time_frame": "baseline,week12"
            }, 
            {
                "measure": "Traditional Chinese Medicine(TCM) characteristics evaluative index: Traditional Chinese medicine Syndrome Scale", 
                "safety_issue": "No", 
                "time_frame": "Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week"
            }, 
            {
                "measure": "The score of  clinical symptoms and symptom integral", 
                "safety_issue": "No", 
                "time_frame": "Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week"
            }, 
            {
                "measure": "Change in the days and doses using of analgesic(Paracetamol Tablets)", 
                "safety_issue": "No", 
                "time_frame": "Taken at day 1 (baseline) and Change from Baseline in 4th,8th,12th week"
            }
        ], 
        "source": "Maoxiang Group Jilin Pharmaceutical Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Maoxiang Group Jilin Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}